Artificial cells for cell and organ replacements.
The artificial cell is a Canadian invention (Chang, Science, 1964). This principle is being actively investigated for use in cell and organ replacements. The earliest routine clinical use of artificial cells is in the form of coated activated charcoal for hemoperfusion for use in the removal of drugs, and toxins and waste in uremia and liver failure. Encapsulated cells are being studied for the treatment of diabetes, liver failure, and kidney failure, and the use of encapsulated genetically-engineered cells is being investigated for gene therapy. Blood substitutes based on modified hemoglobin are already in Phase III clinical trials in patients, with as much as 20 units being infused into each patient during trauma surgery. Artificial cells containing enzymes are being developed for clinical trial in hereditary enzyme deficiency diseases and other diseases. The artificial cell is also being investigated for drug delivery and for other uses in biotechnology, chemical engineering, and medicine.
Chang
Thomas Ming Swi
TM
Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. artcell.med@mcgill.ca
D001187:Artificial Organs; D001802:Blood Substitutes; D002477:Cells; D016503:Drug Delivery Systems / Q000379:methods; D057487:Enzyme Therapy; D005818:Genetic Engineering / Q000379:methods; D006464:Hemoperfusion / Q000379:methods; D006801:Humans; D008567:Membranes, Artificial
D001802:Blood Substitutes; D008567:Membranes, Artificial